EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Role of pentraxin-3 in risk assessment of patients with metabolic syndrome

A Zlibut, I C Bocsan, R M Pop, S C Vesa, K Bheecarry, R Revnic, B Cojan-Minzat, S Lupu, A D Buzoianu, L Agoston-Coldea

Physiology International · 26.09.2019 · 106 (3) · 283-293

DOI: 10.1556/2060.106.2019.18 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Physiology International, erschienen am 26.09.2019. Verfasst von A Zlibut und 9 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammation plays a major role in the development of metabolic syndrome (MetS) and its progression. Recent studies have shown that pentraxin-3 (PTX-3), osteoprogerin (OPG), and tumor necrosis factor-alpha (TNF-α) are key factors in MetS pathophysiology, but evidence for endorsing their clinical use is currently unclear and insufficient.

Aim

The study aimed to evaluate the association between the inflammatory biomarkers’ levels and the severity of MetS.

Methods

The study was observational, transversal, prospective, cohort, and analytical type. We enrolled 80 patients (M:F = 1, mean age = 55 ± 10.77 years) who met MetS criteria. The study protocol included: medical history, physical examination, 6-min walk test distance (6MWTD), biochemical tests, electrocardiogram, echocardiography, and carotid ultrasonography. We also performed plasmatic measurement of PTX-3, OPG, and TNF-α, in addition to standard biochemical tests.

Results

Subjects with severe MetS had higher values of body mass index (BMI) and waist circumference ( p < 0.001, p = 0.001). PTX-3 levels were significantly higher in patients with severe MetS ( p = 0.03) and the values were not influenced by age or gender. OPG positively correlated with BMI ( r = 0.264, p = 0.018). 6MWTD was lower in patients with severe MetS ( p = 0.005), whereas CCA-IMT was higher in this group of patients ( p = 0.005). In addition, the receiver operating characteristic (ROC) curve analysis for PTX-3 identified a cut-off value of 10.7 ng/dl that differentiates between mild and severe MetS [AUC 0.656; sensitivity =47.1% (95% CI = 36.1%–62.3%); specificity = 78.9% (95% CI = 54.4%–93.9%)].

Conclusion

PTX-3 was correlated with the severity of MetS, with other inflammatory parameters and cardiovascular tests. CCA-IMT and 6MWTD are useful in differentiating between mild and severe MetS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersBody Mass IndexC-Reactive ProteinFemaleHumansInflammationMaleMetabolic SyndromeMiddle AgedOsteoprotegerinProspective StudiesROC CurveRisk AssessmentRisk FactorsSerum Amyloid P-ComponentTumor Necrosis Factor-alphaWaist CircumferencePentraxins

Stichwörter der Autor:innen

atherosclerosismetabolic syndromeosteoprotegerinpentraxin-3tumor necrosis factor-alpha

Substanzen

BiomarkersC-Reactive ProteinOsteoprotegerinSerum Amyloid P-ComponentTumor Necrosis Factor-alphaPentraxins

Autor:innen und Institutionen

  • 2nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Department of Community Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Department of Physiology, University of Medicine and Pharmacy, Târgu Mureş, Romania.

Zitieren

APA

Zlibut, A., Bocsan, I. C., Pop, R. M., Vesa, S. C., Bheecarry, K., Revnic, R., Cojan-Minzat, B., Lupu, S., Buzoianu, A. D., & Agoston-Coldea, L. (2019). Role of pentraxin-3 in risk assessment of patients with metabolic syndrome. Physiology International, 106(3), 283-293. https://doi.org/10.1556/2060.106.2019.18

Vancouver

Zlibut A, Bocsan IC, Pop RM, Vesa SC, Bheecarry K, Revnic R, et al. Role of pentraxin-3 in risk assessment of patients with metabolic syndrome. Physiology International. 2019;106(3):283-293. doi:10.1556/2060.106.2019.18

BibTeX
@article{Zlibut2019,
  author = {Zlibut, A and Bocsan, I C and Pop, R M and Vesa, S C and Bheecarry, K and Revnic, R and Cojan-Minzat, B and Lupu, S and Buzoianu, A D and Agoston-Coldea, L},
  title = {Role of pentraxin-3 in risk assessment of patients with metabolic syndrome},
  journal = {Physiology International},
  year = {2019},
  volume = {106},
  number = {3},
  pages = {283--293},
  doi = {10.1556/2060.106.2019.18}
}
Kostenlos starten →